Mannkind Corp. MNKD

What this company does

MannKind Corporation develops and commercializes treatments for cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its cardiometabolic business is comprised of three commercial products: Afrezza (insulin human) Inhalation Powder, Furoscix (furosemide injection), and the V-Go wearable insulin delivery device. Afrezza is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, developed by the company as a dry powder formulation of human insulin delivered from a small portable inhaler. Furoscix is a formulation of furosemide that delivers an 80 mg dose via an on-body infusor over a five-hour period and is indicated for the treatment of edema in pediatric patients who weigh at least 43 kg and adult patients with chronic heart failure or chronic kidney disease. V-Go is a mechanical basal-bolus insulin delivery system worn like a patch that administers a continuous preset basal rate of insulin over 24 hours with on-demand bolus dosing at mealtimes. The company's first product to address an orphan lung disease, Tyvaso DPI (treprostinil) inhalation powder, received FDA approval in May 2022 for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. As of December 31, 2025, it had 592 total at-will employees, of whom 591 were full-time. MannKind Corporation was incorporated in the State of Delaware on February 14, 1991.

Written from the business description in MANNKIND CORP's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.